aclacinomycin
PreclinicalSmall molecule
aclacinomycin is one of 58 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Novantrone
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Novantrone
EMD SeronoPhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Alkeran
AApotex Inc.
Phase 3
Astplayer
AAstex Pharmaceuticals, Inc.
Phase 3
Retin-a
VValeant Pharmaceuticals
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Leukine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia2 trials
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Completed·—·Phase 1/2·NCT01690507·29 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aclacinomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanxi Bethune Hospital